Abstract: The present invention relates to crystalline form I of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form I of the compound represented by chemical formula 1 of the present invention may be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317030838-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [29-04-2023(online)].pdf | 2023-04-29 |
| 2 | 202317030838-STATEMENT OF UNDERTAKING (FORM 3) [29-04-2023(online)].pdf | 2023-04-29 |
| 3 | 202317030838-REQUEST FOR EXAMINATION (FORM-18) [29-04-2023(online)].pdf | 2023-04-29 |
| 4 | 202317030838-FORM 18 [29-04-2023(online)].pdf | 2023-04-29 |
| 5 | 202317030838-FORM 1 [29-04-2023(online)].pdf | 2023-04-29 |
| 6 | 202317030838-DRAWINGS [29-04-2023(online)].pdf | 2023-04-29 |
| 7 | 202317030838-DECLARATION OF INVENTORSHIP (FORM 5) [29-04-2023(online)].pdf | 2023-04-29 |
| 8 | 202317030838-COMPLETE SPECIFICATION [29-04-2023(online)].pdf | 2023-04-29 |
| 9 | 202317030838.pdf | 2023-05-03 |
| 10 | 202317030838-Proof of Right [26-05-2023(online)].pdf | 2023-05-26 |
| 11 | 202317030838-FORM-26 [24-07-2023(online)].pdf | 2023-07-24 |
| 12 | 202317030838-FORM 3 [26-09-2023(online)].pdf | 2023-09-26 |
| 13 | 202317030838-Certified Copy of Priority Document [10-10-2023(online)].pdf | 2023-10-10 |
| 14 | 202317030838-FER.pdf | 2025-02-26 |
| 15 | 202317030838-Others-190325.pdf | 2025-03-21 |
| 16 | 202317030838-Correspondence-190325.pdf | 2025-03-21 |
| 17 | 202317030838-FORM 3 [15-04-2025(online)].pdf | 2025-04-15 |
| 18 | 202317030838-Information under section 8(2) [26-04-2025(online)].pdf | 2025-04-26 |
| 19 | 202317030838-FORM 4 [20-08-2025(online)].pdf | 2025-08-20 |
| 1 | 202317030838_SearchStrategyNew_E_Search202317030838E_25-02-2025.pdf |